ASTRAZENECA PHARMA INDIA LTD
Add to watch list to get report alerts
BSE Code:
506820
NSE Code:
ASTRAZEN
Business Profile
Business Profile
AstraZeneca Pharma India (ASTRAZEN) provides a range of pharmaceutical products in six areas of healthcare - gastrointestinal, cardiovascular, cancer, respiratory, neurosciences and infection. It was incorporated on July. 11, 1979 and promoted jointly by Astra Pharmaceuticals AB, Sweden and IDL Chemicals, Hyderabad. It got its current name in 2001. The managing director of the company is Anand Balasundaram.
The company offer products for cardiovascular (Betaloc, Seloken XL, Imdur, Ramace, Plendil, etc); respiratory (Rhinocort, Mits Linctus, Bricarex, Bricanyl); maternal healthcare (Prostodin, Cerviprime, Primiprost, Partocin, etc); oncology (Zoladex and Arimidex, Nolvadex, Iressa and Casodex, etc); infection (Meronem and Vancocin CP, etc). The manufacturing facility in Yelahanka, Bangalore has been rated as one of the finest in South East Asia. It has a sophisticated production facility designed to meet the most stringent international standards, conforming to WHO cGMP norms.
The company is ISO 14001 certified and has a full-fledged environment management system in place. The company is an integral part of the global organization with the mandate to discover new chemical entities for the treatment of infectious diseases. The new state-of-the-art global process R&D lab in Bangalore is for this purpose. The company has won awards like the Golden Peacock Environment Management Award from World Environment Foundation for the year 2004-2005; the 2006 Indian Manufacturing Excellence Platinum Award in healthcare; and the Best Safe Industry by National Safety Council, (Karnataka Chapter) in 2007.
The registered office is at Crescent Towers, 32/1-2 Crescent Road, Bangalore-560001.
Financials
Astrazeneca Pharma India registered a 8.41% growth in net profit to Rs 145.79 million for the quarter ended June 2007 from a profit of Rs 134.48 million for the quarter ended June 2006.
Net sales rose 12.85% to Rs 804.1 million for the quarter ended June 2007 from Rs 712.57 million for the quarter ended June 2006.
Total income rose 14.20% to Rs 829.32 million for the quarter ended June 2007 from Rs 726.19 million for the quarter ended June 2006.
The earnings per share (EPS) of the company stood at Rs 5.83 for the quarter ended June 2007.